CADTH Canadian drug expert committee recommendation: Upadacitinib (Rinvoq -- abbVie) indication : for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate
The CADTH Canadian Drug Expert Committee (CDEC) recommends that upadacitinib be reimbursed for use as monotherapy or in combination with methotrexate or other conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) for the treatment of adult patients with moderately to severely activ...
| Corporate Authors: | , |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2020, February 2020
|
| Edition: | Version: 1.0 |
| Series: | CADTH common drug review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The CADTH Canadian Drug Expert Committee (CDEC) recommends that upadacitinib be reimbursed for use as monotherapy or in combination with methotrexate or other conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA), if the following conditions are met : Conditions for Reimbursement, initiation Criteria 1. Adult patients with moderately to severely active RA on stable doses of disease-modifying antirheumatic drugs (DMARDs) who have had inadequate response or intolerance to methotrexate. 2. Upadacitinib should not be used in combination with other biologic DMARDs (bDMARDs) or Janus kinase (JAK) inhibitors |
|---|---|
| Item Description: | "Final." |
| Physical Description: | 1 PDF file (9 pages) |